A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer

NCT00336700 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

25

Enrollment

OTHER

Sponsor class

Stopped Study published November 2010 and no further work will be done

Conditions

Pancreatic Cancer

Interventions

DRUG: Gemcitabine
DRUG: Erlotinib

Sponsor

Herbert J. Zeh, III MD, FACS

Collaborators

[object Object]